(Q43633583)

25 November 2017

title

Production of anti-CD3 and anti-CD7 ricin A-immunotoxins for a clinical pilot study (English)

1 reference

25 November 2017

van Oosterhout YV

1

1 reference

25 November 2017

van Emst JL

2

1 reference

25 November 2017

Bakker HH

3

1 reference

25 November 2017

Preijers FW

4

1 reference

25 November 2017

Schattenberg AV

5

1 reference

25 November 2017

Ruiter DJ

6

1 reference

25 November 2017

Evers S

7

1 reference

25 November 2017

Koopman JP

8

1 reference

25 November 2017

de Witte T

9

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

International Journal of Pharmaceutics

25 November 2017

published in

1 reference

25 November 2017

volume

221

1 reference

25 November 2017

issue

1-2

1 reference

25 November 2017

page(s)

175-186

1 reference

Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900684-6

7 January 2021

Distribution of endocytosed molecules to intracellular acidic environments correlates with immunotoxin activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900684-6

7 January 2021

The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bond.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900684-6

7 January 2021

Immunotoxins in the therapy of cancer: from bench to clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900684-6

7 January 2021

An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900684-6

7 January 2021

Immunotoxins in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900684-6

7 January 2021

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900684-6

7 January 2021

Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900684-6

7 January 2021

Intracellular routing rather than cross-linking or rate of internalization determines the potency of immunotoxins directed against different epitopes of sIgD on murine B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900684-6

7 January 2021

Relationship between internalization and cytotoxicity of ricin A-chain immunotoxins

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900684-6

7 January 2021

A simplified microassay for inhibition of protein synthesis in reticulocyte lysates by immunotoxins

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900684-6

7 January 2021

Characterization of monoclonal antibodies against cell surface molecules associated with cytotoxic activity of natural and activated killer cells and cloned CTL lines.

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900684-6

7 January 2021

Cytotoxic potency of CD22-ricin A depends on intracellular routing rather than on the number of internalized molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900684-6

7 January 2021

Immunotoxins: magic bullets or misguided missiles?

1 reference

https://api.crossref.org/works/10.1016%2FS0378-5173%2801%2900684-6

7 January 2021

10.1016/S0378-5173(01)00684-6

Identifiers

DOI

1 reference

25 November 2017

1 reference